Otsuka Pharmaceutical Companies (U.S.) | Company Profile, Culture & Jobs

Company overview

There are two Otsuka pharmaceutical industry companies in the U.S.:Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America.Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.

Founded in 1989

Princeton, New Jersey, USA

3.6K employees (162 in marketing)

www.otsuka-us.com

Salaries

Typical salary range

$131,153 – $196,075

/ yr

Median base

$303,500

Median total

$303,500

Median experience

12 years

Submissions

4

Help build salary transparency at Otsuka Pharmaceutical Companies (U.S.)

Share your compensation anonymously to see full data.

Contribute

People

Marketing leadership

Neveen Abou-Gharbia, PharmD, MBA

Executive Director, CNS Marketing Brand Head (MDD)

At the company for 15 years 4 months

Rich Dunn

Head of Talent Acquisition

At the company for 6 years 7 months

Kristin Emard

Associate Director Brand Analytics – Nephrology & Rare Disease

At the company for 4 years 9 months

Heather Marshall

Senior Manager Talent Acquisition

At the company for 4 years 3 months

Hiring contacts

Rich Dunn

Head of Talent Acquisition

At the company for 6 years 7 months

Heather Marshall

Senior Manager Talent Acquisition

At the company for 4 years 3 months

Hiring activity

Open marketing jobs over time

10 open now

Headcount trend

Company growth over the last 12 months

Audience

Monthly website visitors

118K

Month over month+9%

Quarter over quarter+40%

Top sourceDirect (56%)

Ad budget per month$0.0

Average search rank46.5

Traffic source mix

Direct

56%

Search

35.5%

News

Otsuka’s IgAN therapy gets a thumbs-up from the FDA

Nov 26, 2025 • BioWorld MedTech

Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression

Nov 26, 2025 • BioSpace

US FDA approves Otsuka’s drug for a type of kidney disease

Nov 25, 2025 • pharmalive.com

Links

www.otsuka-us.com

Crunchbase

X (Twitter)

Otsuka Pharmaceutical Companies (U.S.) insights

Company and marketing-team signals from saved company data and employee profiles. Use this before you apply, interview, or negotiate.

Founded

1989

Headquarters

Princeton, New Jersey

Employees

1001-5000

Flat last 12mo

Marketing team

162

5% of company

20 saved employee profiles are linked to this company.

Company stability and risk

Shows a quick risk view from growth, funding age, and news.

Main result

Low risk

Seed-stage · Flat headcount last 12 months · More mature

Trend

2022-02-28 -> 2025-11-24

Headcount (12 months)

+0.9%

Last funding round

—

Negative news (120 days)

0

Risk score0/7

Website traffic

Shows traffic size, change, and traffic sources.

Monthly website visitors

118K

Month over month+9%

Quarter over quarter+40%

Top sourceDirect (56%)

Traffic source mix

Direct

56%

Search

35.5%

Referral

Competitors and search

Shows competitors and key search metrics in one view.

Main result

49 competitor sites

Search traffic: 9.5K organic clicks / 0 paid clicks

Organic competitors

0

Paid competitors

0

Keyword change

+460

Ad budget per month

$0.0

Average search rank

46.5

LinkedIn followers

Shows follower count and growth.

LinkedIn followers

Follower count and growth

Total followers

235.6K

12-mo growth

+15.9%

Monthly growth

Job openings

Shows open jobs, growth, and role changes.

Main result

4 open jobs

Open jobs trend: —

Trend

Marketing team size

Shows saved marketing team size.

162

5% of the company • 20 saved marketing people

First hire or larger team

Shows if this looks like one hire or a bigger team.

Looks like larger team

Based on saved marketing team size: 162.

News

Shows saved company news.

Otsuka’s IgAN therapy gets a thumbs-up from the FDA

Nov 26, 2025 • BioWorld MedTech

Otsuka Receives FDA Accelerated Approval for VOYXACT® (sibeprenlimab-szsi) for the Reduction of Proteinuria in Adults with Primary Immunoglobulin A Nephropathy (IgAN) at Risk for Disease Progression

Nov 26, 2025 • BioSpace

US FDA approves Otsuka’s drug for a type of kidney disease

Nov 25, 2025 • pharmalive.com

Loading insights...

Headcount +0.9% year over year

Referral

6.7%

Social

1%

Paid referral

0.7%

LinkedIn followers

Follower count and growth

Total followers

235.6K

12-mo growth

+15.9%

Monthly growth

+1.1%